Cassava Sciences Announces Leadership Changes
AUSTIN, Texas — Cassava Sciences, Inc. (NASDAQ: SAVA), a pioneering biotechnology company, is excited to announce significant changes in its leadership team aimed at enhancing its clinical development efforts. The company is dedicated to discovering innovative treatments for central nervous system disorders, with a focus on their investigational drug, simufilam, intended to address conditions such as tuberous sclerosis complex-related epilepsy.
Dr. Jim Kupiec Retires After a Distinguished Career
Cassava Sciences is extending its heartfelt gratitude to Dr. James W. Kupiec, who is retiring as Chief Medical Officer, effective May 9. Dr. Kupiec has made notable contributions to the company, particularly in the realm of Alzheimer’s disease drug development. His commitment to patient care and strong reputation in the scientific community has been instrumental in leading up the company's successful clinical trial programs.
Reflections from the CEO
Rick Barry, the CEO of Cassava, remarked on Jim's retirement, stating, "We are thankful for Jim's contributions during his tenure as Chief Medical Officer. He has been a key figure in ensuring our clinical trials uphold high ethical standards while prioritizing the welfare of patients and their families. We wish him a joyful retirement and all the best in his future endeavors."
Welcome Dr. Jack Moore
Cassava is also excited to welcome Dr. Jack Moore as the new Senior Vice President of Clinical Development, effective April 28. Dr. Moore brings with him extensive experience in clinical development and a proven track record from various leading pharmaceutical companies. His primary focus will be to advance the research and clinical evaluation of simufilam for potential new indications, particularly those related to TSC.
Expertise in CNS Disorders
With a robust background in managing clinical development strategies for CNS and neurodegenerative diseases such as multiple sclerosis and Alzheimer’s, Dr. Moore is well-equipped to drive Cassava’s clinical initiatives. He previously held pivotal leadership roles in well-known organizations, including Alector Inc., Janssen Pharmaceutica, and Novartis, making his transition to Cassava a strategic move for the company.
Statements from Dr. Jack Moore
Expressing his enthusiasm, Dr. Jack Moore stated, "I am thrilled to join Cassava and contribute my expertise to the clinical development of simufilam, especially in its application for TSC and other conditions. I look forward to working collaboratively with the team to advance our projects and make a difference in patients’ lives."
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA) specializes in creating innovative treatments for central nervous system disorders. Their investigational drug, simufilam, is an oral small molecule that targets the filamin A protein, playing a vital role in addressing conditions like TSC-related epilepsy. Based in Austin, Texas, Cassava is committed to advancing its clinical programs and contributing positively to the healthcare landscape.
Frequently Asked Questions
1. Who is the new Chief Medical Officer at Cassava Sciences?
Dr. Jim Kupiec has announced his retirement as Chief Medical Officer, and Dr. Jack Moore has been appointed as Senior Vice President for Clinical Development.
2. What is simufilam?
Simufilam is an investigational oral small molecule treatment developed by Cassava Sciences aimed at various central nervous system disorders.
3. What are Dr. Moore's qualifications?
Dr. Jack Moore has extensive experience in CNS drug development, having held key positions at several major pharmaceutical companies, including Alector and Janssen.
4. What does the leadership change mean for Cassava Sciences?
The leadership change is intended to strengthen clinical development and exploration of new potential applications for simufilam.
5. How can investors contact Cassava Sciences?
Investors can reach out directly to Cassava Sciences via email at IR@cassavasciences.com for inquiries.
